|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
In humans, severe hyperhomocysteinemia due to genetic alterations in cystathionine beta-synthase (Cbs) or methylenetetrahydrofolate reductase (Mthfr) results in neurological abnormalities and premature death from vascular complications.
|
19204075 |
2009 |
|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
MTHFR 677C/T polymorphism is associated with the risk of vascular diseases due to hyperhomocysteinemia.
|
19646848 |
2009 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
MTHFR 677C/T polymorphism is associated with the risk of vascular diseases due to hyperhomocysteinemia.
|
19646848 |
2009 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
In humans, severe hyperhomocysteinemia due to genetic alterations in cystathionine beta-synthase (Cbs) or methylenetetrahydrofolate reductase (Mthfr) results in neurological abnormalities and premature death from vascular complications.
|
19204075 |
2009 |
|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
After MTX treatment, MTHFR-Tg mice exhibited the same decreases in hematological parameters as Mthfr-deficient mice, and significantly decreased thymidine synthesis (higher 2'-deoxyuridine 5'-triphosphate/2'-deoxythymidine 5'-triphosphate ratios) compared with wild-type mice, but they were protected from MTX-induced hyperhomocysteinemia.
|
18551038 |
2008 |
|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.
|
17387702 |
2008 |
|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
In this study, we investigated the levels of serum folate, vitamin B-12 and Hcy in epileptic patients receiving carbamazepine (CBZ) or valproic acid (VPA) as monotherapy, and we also evaluated the probable contribution of the C677T variant of MTHFR gene in hyperhomocysteinemia.
|
18234410 |
2008 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
After MTX treatment, MTHFR-Tg mice exhibited the same decreases in hematological parameters as Mthfr-deficient mice, and significantly decreased thymidine synthesis (higher 2'-deoxyuridine 5'-triphosphate/2'-deoxythymidine 5'-triphosphate ratios) compared with wild-type mice, but they were protected from MTX-induced hyperhomocysteinemia.
|
18551038 |
2008 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.
|
17387702 |
2008 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
In this study, we investigated the levels of serum folate, vitamin B-12 and Hcy in epileptic patients receiving carbamazepine (CBZ) or valproic acid (VPA) as monotherapy, and we also evaluated the probable contribution of the C677T variant of MTHFR gene in hyperhomocysteinemia.
|
18234410 |
2008 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Methylenetetrahydrofolate reductase polymorphisms and homocysteine-lowering effect of vitamin therapy in Singaporean stroke patients.
|
16397167 |
2006 |
|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Methylenetetrahydrofolate reductase polymorphisms and homocysteine-lowering effect of vitamin therapy in Singaporean stroke patients.
|
16397167 |
2006 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Maternal polymorphisms 677C-T and 1298A-C of MTHFR, and 66A-G MTRR genes: is there any relationship between polymorphisms of the folate pathway, maternal homocysteine levels, and the risk for having a child with Down syndrome?
|
16575899 |
2006 |
|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Maternal polymorphisms 677C-T and 1298A-C of MTHFR, and 66A-G MTRR genes: is there any relationship between polymorphisms of the folate pathway, maternal homocysteine levels, and the risk for having a child with Down syndrome?
|
16575899 |
2006 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
The glycine N-methyltransferase (GNMT) 1289 C->T variant influences plasma total homocysteine concentrations in young women after restricting folate intake.
|
16317120 |
2005 |
|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
The glycine N-methyltransferase (GNMT) 1289 C->T variant influences plasma total homocysteine concentrations in young women after restricting folate intake.
|
16317120 |
2005 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Splenic thrombosis in three patients with moderate hyperhomocysteinemia, low folate and the C677T variant of the methylenetetrahydrofolate reductase (MTHFR) gene.
|
16411416 |
2005 |
|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Splenic thrombosis in three patients with moderate hyperhomocysteinemia, low folate and the C677T variant of the methylenetetrahydrofolate reductase (MTHFR) gene.
|
16411416 |
2005 |
|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
C677T polymorphism in methylenetetrahydrofolate reductase gene (MTHFR) is a major determinant of hyperhomocysteinemia, which results in endothelial dysfunction.
|
15226090 |
2004 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
C677T polymorphism in methylenetetrahydrofolate reductase gene (MTHFR) is a major determinant of hyperhomocysteinemia, which results in endothelial dysfunction.
|
15226090 |
2004 |
|
Hyperhomocysteinemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Multiple logistic regression analysis showed that MTHFR TT genotype was an independent predictor of hyperhomocysteinemia in epileptic patients receiving anticonvulsants (phenytoin and carbamazepine but not valproic acid), suggesting that gene-drug interactions induce hyperhomocysteinemia.
|
10459572 |
1999 |
|
Hyperhomocysteinemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Multiple logistic regression analysis showed that MTHFR TT genotype was an independent predictor of hyperhomocysteinemia in epileptic patients receiving anticonvulsants (phenytoin and carbamazepine but not valproic acid), suggesting that gene-drug interactions induce hyperhomocysteinemia.
|
10459572 |
1999 |